AVANTECA Partners
VC Fund
Basel, Switzerland
Avanteca Partners is an asset management company investing in early-stage Life Science companies.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries AVANTECA Partners invests in
Stages AVANTECA Partners invests in
Countries AVANTECA Partners invests in
Round sizes
Round size
- Seed
- $805k–$4.6M
Investment Focus
Industry
- Biotechnology 4 (57%)
- Health Care 3 (43%)
- Security 1 (14%)
- Biopharma 1 (14%)
- Public Safety 1 (14%)
Stage
- Seed 4 (57%)
- Series A 1 (14%)
- Venture - Series Unknown 1 (14%)
Country
- Switzerland 3 (43%)
- Spain 2 (29%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nanoligent
|
Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively targetthe cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. | $14.1M / Series A / Oct 06, 2025 | |
Onena Medicines
|
Onena Medicines is a biotechnology company that creates innovative biological medicines to address the large unmet clinical need for breast cancer and other serious orphan illness. | $4.1M / Venture - Series Unknown / Oct 31, 2023 | |
Bearmind
|
Bearmind developing technology for monitoring and real-time analysis of head impact in athletes. | $804.6K / Seed / Jul 24, 2023 | |
|
Bearmind
|
Bearmind developing technology for monitoring and real-time analysis of head impact in athletes. | $1.4M / Seed / Mar 07, 2023 | |
Invasight
|
Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland. | $4.6M / Seed / Jun 07, 2022 | |
|
Nanoligent
|
Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively targetthe cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. | $1.1M / Seed / Feb 03, 2022 | |
Oncobit
|
Oncobit enabling personalized cancer care by developing precise and highly sensitive diagnostic and monitoring tests. | $2.5M / Seed / Apr 30, 2021 |
Co-Investors
Verve Ventures
2 deals together
Zürcher Kantonal Bank
2 deals together
CDTI Innovación's INNVIERTE program
1 deal together
Clave Capital
1 deal together
GF Group Holding
1 deal together
H. Hentsch Asset Management
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does AVANTECA Partners invest in?
AVANTECA Partners invests primarily in Biotechnology, Health Care and Security startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is AVANTECA Partners's check size?
AVANTECA Partners typically joins rounds of $805k–$4.6M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds AVANTECA Partners participates in.
When did AVANTECA Partners last invest?
The most recent investment recorded for AVANTECA Partners closed in Oct 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
